Nobivac Canine Flu Bivalent vaccine

Merck Animal Health has announced USDA approval of a license for Nobivac Canine Flu Bivalent vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8. Since CIV H3N2 cases were first reported in March 2015, dogs in more than half of the United States have been stricken by this respiratory disease. CIV H3N8 was first diagnosed in 2004 and has impacted dogs in more than 40 states. Nobivac Canine Flu Bivalent is recommended for healthy dogs 7 weeks of age or older. For fastest response visit doginfluenza.com

556 Morris Avenue Summit, NJ 07901
Tel: (800) 224-5318